The results suggested that chemotherapy may reduce EGFR mutation frequencies in patients with NSCLC, a likely result of a preferential response of sub-clones with EGFR mutations in tumors with heterogeneous tumor cell populations [13]. Here, EGFR is linked to neoplasm.